Tobias Krickau

CD19-targeting CAR T-cell therapy in patients with diffuse systemic sclerosis: a case series

Janina Auth, Fabian Müller, Simon Völkl et al. · The Lancet Rheumatology · 2024 · 99 citations · Full text

Life Sciences, Clinical Sciences, Immunology +15

Local immune effector cell-associated toxicity syndrome in CAR T-cell treated patients with autoimmune disease: an observational study

Melanie Hagen, Fabian Müller, Andreas Wirsching et al. · The Lancet Rheumatology · 2025 · 71 citations · Full text

Life Sciences, Immunology, Autoimmunity +16

Comparison of the safety profiles of CD19-targeting CAR T-cell therapy in patients with SLE and B-cell lymphoma

Fabian Müller, Nora Rebecca Schwingen, Melanie Hagen et al. · Blood · 2025 · 28 citations

Life Sciences, Hematology, Immunology +17

Long-term safety and effectiveness of canakinumab in patients with monogenic autoinflammatory diseases: results from the interim analysis of the RELIANCE registry

Jasmin Kuemmerle‐Deschner, Tilmann Kallinich, Jörg Henes et al. · RMD Open · 2024 · 16 citations · Full text

Life Sciences, Immunology, Pharmacotherapy +17

Anti-CD19 CAR T cells for pediatric patients with treatment-refractory autoimmune diseases

Marco Becilli, Markus Metzler, Rebecca Nicolai et al. · Nature Medicine · 2026 · 10 citations

Life Sciences, Immunology, Pediatrics +16